Motivation While Photofrin PDT is an approved oncological therapy for multiple indications, its wider use is hindered by prolonged skin photosensitivity lasting several weeks. The aim of this study is to investigate intratumoral Photofrin administration as a way to decrease skin photosensitivity compared to the standard IV injection protocol. Tumor necrosis after PDT was assessed with immunohistochemical staining and Photofrin distributions by fluorescence microscopy. Results Anti-tumor efficacy was similar between intratumoral and IV administration; however, smaller doses of Photofrin were
Continue reading →Customer case University of Rochester belongs among the nation’s top research universities. Research at the Baran lab focuses on anti-microbial PDT and optical image processing. The aim is to develop methods for utilizing quantitative information from CT, MR and PET imaging for PDT treatment planning as well as in the search of new biomarkers and therapeutic targets. Modulight products: ML7710 (630 & 665 nm) Link to the study: Timothy M. Baran (Ph.D., PI) Laser use: Ongoing clinical Phase 1 safety & feasibility study for methylene
Continue reading →
Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the invasive cancer cells within 2 cm of the resected area where the glioblastoma most often recurs. However, a significant hurdle of this therapy modality is the limited light penetration depth
Continue reading →Customer case Research by: University of Maryland, Optical Therapeutics & Nanotechnology Laboratory led by Prof. Huang. Research focuses on precision cancer nanomedicine, drug delivery strategies, overcoming cancer resistance, mechanism-based combination therapies, site-directed photochemistry and fluorescence diagnostics. Modulight has started a joint R&D program with Dr. Huang lab to study novel EGFR-targeted combination therapy/diagnostic agent PIC-Nal-IRI developed by Huang lab. Modulight products: ML6600 laser system (635 nm and 689 nm). Professor Huang-Chiao Huang Laser use: Targeted photodynamic therapy/photoimmunotherapy with benzoporphyrin derivative (BPD) & 5-aminolevulinic acid (5-ALA) photosensitizers.
Continue reading →
Results Illumination with one fiber Some level of tissue heating was observed at all used light intensities. At lower intensities (60-100 mW/cm), less than 5% of the tumor was subjected to >60 ⁰C temperature, a point where irreversible thermal damage will immediately occur (photothermal ablation). At intensities of 150-200 mW/cm, 15-20% of the tumor was at >60 ⁰C temperature. At 400 mW/cm, which is FDA-recommended light irradiance for iPDT, a substantial portion of the tumor, up to 60%, was above 60 ⁰C. Above figures
Continue reading →Customer case Roswell Park Comprehensive Cancer Center was founded in 1898 as the first institute in the US devoted exclusively to cancer treatment and research. It is also the place where photodynamic therapy (PDT) was developed in the late 1970s by Thomas Dougherty. The PDT center at Roswell Park is a leader in the use of photodynamic therapy for treating different cancers. Research work includes treatment planning and light dosimetry for interstitial and intraoperative PDT to improve the quality of life and survival of cancer patients
Continue reading →
Related Modulight products and Services Related Publications Light emitting fabrics for PDT: technology and results of clinical studies Serge R. Mordon, Elise Thecua, Fabienne Lecomte, Anne-Sophie Vignion-Dewalle, Pascal Deleporte, Cyril Maire, Henry Abi-Rached, Claire Vicentini, Theresa Hommel, R. Markus Szeimies, Laurent Mortier SPIE, 2019 Photodynamic Therapy Using a New Painless Light-Emitting Fabrics Device in the Treatment of Extramammary Paget Disease of the Vulva (the PAGETEX Study): Protocol for an Interventional Efficacy and Safety Trial Fabienne Lecomte, Elise Thecua, Laurine Ziane, Pascal
Continue reading →Customer case Research by: Laser-assisted therapies and immunotherapies for oncology (OncoThAI) center at University of Lille is a large research center that carries fundamental and translational projects with the aim to widely implement PDT to clinical use either alone or in combination with other therapies like surgery or immunotherapy. Modulight products: ML7710 (631, 635, 665 nm) Laser use: Light-emitting fabrics for PDT therapy at clinical level Prof. Serge Mordon PhD, currently at BioTis/Inserm Dr. Laurent Mortier, MD, PhD, University of Lille Research
Continue reading →
Background Professor Stummer on glioblastoma surgeries and iPDT: Treatment protocol 20 patients were treated. 5-ALA (Gliolan) was administered at a dosage of 20 mg/kg body weight 4 hours before anesthesia. Craniotomy was performed using FGR, with aim of maximal safe resection of the fluorescent tumor. Once there was no visible fluorescence or only tumor-infiltrated fluorescence in the eloquent areas left, PDT was performed. 1-4 cylindrical diffuser were strategically inserted depending on the size and architecture of the resection cavity and fixed to a
Continue reading →Customer case Research by: University Hospital Münster provides cutting-edge medical treatments for patients all over the world. The department of neurosurgery provides a full spectrum of neurosurgical care with interdisciplinary vascular and neuro-oncological specialization. Modulight products: ML7710, ML7710i Laser use: Randomized controlled PDT trials for both newly diagnosed and recurrent glioblastoma, as well as compassionate care for terminal glioblastoma patients. Link to the study: Professor Walter Stummer, MD, PhD Research topics: Professor Stummer is a world leader in his research fields, which include vascular neurosurgery, microneurosurgery,
Continue reading →
Retinal Physician – May 1, 2021 Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight.Retinal Physician - May 1, 2021 Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight. Read article
BRIDGEWATER, N.J., December 04, 2018 – Bausch + Lomb, a leading global eye health company, and Modulight, Inc., a designer and manufacturer of lasers and optics for personalized medicine, announced the companies have entered into an exclusive agreement to collaborate and develop a new photodynamic laser specifically designed for use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) therapy. “Photodynamic therapy continues to be an important option for eye care professionals who treat choroidal neovascularization in patients who suffer from persistent disease activity, but the availability of lasers capable
Continue reading →
Time: Wed 15.6.2016, 8:30–11:00 Place: Hotel Kämp, Helsinki Paavo Nurmi cabinet Pohjoisesplanadi 29, Helsinki, Finland Confirmed speakers Lecture slideshows Click here to view our previous workshop at ASLMS-2015. Related products: ML7710 – the tool for professionals » | Products for oncology » | ML8500 automatic illumination system » | Illumination kit »Time: Wed 15.6.2016, 8:30–11:00 Place: Hotel Kämp, Helsinki Paavo Nurmi cabinet Pohjoisesplanadi 29, Helsinki, Finland Confirmed speakers Prof. Eero Mervaala: Optogenetics in cardiology and cardiotoxicity Professor, Pharmacology, University of Helsinki Professor Mervaala works in the field of cardiovascular and metabolic pharmacology in the Department of Pharmacology, University of Helsinki, Finland. Prof. Teuvo Tammela: Prostate cancer therapy with laser as part of combinatory treatment Professor in Urology, Tampere University Dr. Teuvo Tammela is a specialist in urology and surgery. He is a meritorious scientist especially
Continue reading →
San Jose, California & Tampere FINLAND, September 15, 2015 – Modulight, Inc., a leading biomedical laser manufacturer, announces today a rising star in immunotherapy competition. The objective is to help clinicians and biomedical researchers below 35 years old to get their hands on the best possible tools to support photo immunotherapy. All clinicians, residents and biomedical researchers worldwide are eligible to participate the contest by submitting their application via web (research plan, CV and publication list). Final selection of the winner will be done by an independent board of
Continue reading →
There is no excerpt because this is a protected post.Fri 24th April 6 pm, Gaylord Palms Resort, Kissimmee, FL Topics PDT dosimetry – Dr. Gal Shafirstein, Roswell Park Cancer Center, Buffalo, NY [embeddoc url="https://modulight.com/wp-content/uploads/2015/08/ASMLS-2015-PDT-Workshop-Prof.-Shafirstein-Final.pptx" width="280px" height="210px" download="all" viewer="microsoft"] Head & Neck – Dr. Merrill Biel, University of Minnesota Medical School, Minneapolis, MN Cholangiocarsinoma & Esophageal – Dr. Herbert C. Wolfsen, Mayo Clinic, Jacksonville, FL [embeddoc url="https://modulight.com/wp-content/uploads/2015/08/ASLMS_2015_Jones-Wolfsen.pptx" width="280px" height="210px" download="all" viewer="microsoft] Thoracic PDT – Dr. Patrick Ross Jr, The Ohio State University, Columbus, OH Mesothelioma – Dr. Keith Cengel, Perelman School of Medicine, Philadelphia, PA Breast – Dr.
Continue reading → 
